$500M annual run-rate cost savings by end of 2027
Company: Core Scientific
The claim, verbatim
The deal is expected to add about $500 million of fully ramped annual run-rate cost savings by the end of 2027. This figure includes the elimination of lease overhead.
Source (primary)
core-scientific 8-K exhibit (d52423dex991.htm) (SEC EDGAR (8-K Ex), press_release)
View cached copy (2026-10-11)Live source ↗
Quote: “Including the elimination of the lease overhead, this deal adds $500 million of estimated fully ramped, annual run rate cost savings by the end of 2027 through streamlined operational focus.”
How we checked this
Checked on October 15, 2026. The cited source supports every part of this claim.
The release states the estimated $500 million in annual run-rate cost savings by end of 2027, including the eliminated lease overhead.
Confirmed in the source:
- The deal adds an estimated $500 million of fully ramped annual run-rate cost savings
- The savings are expected by the end of 2027
- The $500 million figure includes the elimination of lease overhead
What we did: Read our cached copy of SEC EDGAR (8-K Ex) (https://www.sec.gov/Archives/edgar/data/1839341/000119312525155925/d52423dex991.htm) in full (19,368 characters, retrieved October 11, 2026) and checked each assertion in the claim against it.
Additional evidence
confirms core-scientific 8-K exhibit (d52423dex991.htm)
Quote: “Including the elimination of the lease overhead, this deal adds $500 million of estimated fully ramped, annual run rate cost savings by the end of 2027 through streamlined operational focus.”